FBRX Forte Biosciences Inc

Price (delayed)

$16.61

Market cap

$340.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.64

Enterprise value

$281.93M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and ...

Highlights
FBRX's EPS has soared by 51% YoY
The equity has contracted by 31% from the previous quarter but it has grown by 10% YoY
The net income has plunged by 74% YoY and by 9% from the previous quarter
FBRX's quick ratio has dropped by 52% year-on-year and by 34% since the previous quarter

Key stats

What are the main financial stats of FBRX

FBRX stock price

How has the Forte Biosciences stock price performed over time
Intraday
-2.29%
1 week
-20.03%
1 month
-41.74%
1 year
66.52%
YTD
-39.09%
QTD
-35.87%

Financial performance

How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$76.97M
Net income
-$75.86M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 74% YoY and by 9% from the previous quarter
The operating income has plunged by 71% YoY and by 9% from the previous quarter

Price vs fundamentals

How does FBRX's price correlate with its fundamentals

Growth

What is Forte Biosciences's growth rate over time

Valuation

What is Forte Biosciences stock price valuation
P/E
N/A
P/B
5.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS has soared by 51% YoY
The price to book (P/B) is 195% higher than the 5-year quarterly average of 1.9 and 30% higher than the last 4 quarters average of 4.3
The equity has contracted by 31% from the previous quarter but it has grown by 10% YoY

Efficiency

How efficient is Forte Biosciences business performance
FBRX's return on equity is up by 29% year-on-year but it is down by 8% since the previous quarter
The company's return on assets rose by 25% YoY but it fell by 3.3% QoQ

Dividends

What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBRX.

Financial health

How did Forte Biosciences financials performed over time
FBRX's total assets is 168% greater than its total liabilities
The company's total liabilities has surged by 178% YoY and by 15% QoQ
FBRX's quick ratio has dropped by 52% year-on-year and by 34% since the previous quarter
Forte Biosciences's debt is 100% less than its equity
The equity has contracted by 31% from the previous quarter but it has grown by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.